The impact of major depressive disorder on the short‐ and long‐term outcome of Crohn's disease treatment with infliximab
Open accessAbstract
Summary: Background: Major depressive disorder is the most common psychiatric diagnosis in Crohn's disease. In other chronic diseases, evidence suggests that depression influences the course of the disease. Strong evidence of such a mediating role of major depressive disorder in Crohn's disease has never been found. Aim: To assess the relationship between major depressive disorder and outcome of treatment of luminal Crohn's disease with infliximab. Methods: In this prospective study, 100 consecutive unselected patients underwent assessment of psychosocial, demographical disease‐related biological and clinical parameters at baseline and at 4 weeks after infliximab. Major depressive disorder was diagnosed using the Patient Health Questionnaire. Subsequently, the patients were followed up clinically until the next flare or during 9 months. Results: The Crohn's disease responded in 75% of the patients, and remission was achieved in 60%. The presence of major depressive disorder at baseline predicted a lower remission rate (OR = 0.166, 95% CI = 0.049–0.567, P = 0.004). At follow‐up, 88% of the patients needed retreatment. At univariate regression analysis, major depressive disorder significantly decreased time to retreatment (P = 0.001). Multivariate Cox regression confirmed major depressive disorder as an independent determinant of active disease both at baseline and at re‐evaluation (hazard ratio = 2.271, 95% CI: 1.36–3.79, P = 0.002). Conclusion: Major depressive disorder is a risk factor for failure to achieve remission with infliximab and for earlier retreatment in patients with active luminal Crohn's disease. Assessment and management of major depressive disorder should be part of the clinical approach to patients with Crohn's disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Whereas only 43% of patients in the placebo group experienced clinically significant improvements in fatigue at Week 12, 58% of those in the etanercept group experienced such improvements.
“whereas only 43% of patients in the placebo group experienced clinically significant improvements in fatigue at Week 12, 58% of those in the etanercept group experienced such improvements”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Persoons et al., 2005
The Study protocol and Results (pages unavailable) describe infliximab treatment for Crohn’s disease and assessment at four weeks. Searches for etanercept, placebo, Week 12, and clinically significant fatigue improvement found no passage reporting the claimed 43% and 58% comparison. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139 · see citing works
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910 · see citing works
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177 · see citing works
Depression and Pain Comorbidity: A Literature Review
Bair, M. J., Robinson, R. L., Katon, W., & Kroenke, K. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.20.2433 · Cited by 3,463 · see citing works
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135 · see citing works
Self-citationInfliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,748 · see citing works
Self-citationThe twenty-item Toronto Alexithymia scale—II. Convergent, discriminant, and concurrent validity
Bagby, R. M., Taylor, G. J., & Parker, J. D. A. (1994) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)90006-x · Cited by 2,431 · see citing works
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,222 · see citing works
Self-citationThe Relationship of Depression to Cardiovascular Disease: Epidemiology, Biology, and Treatment
Musselman, D. L., Evans, D. L., & Nemeroff, C. B. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.580 · Cited by 1,532 · see citing works
Gasché, C., Schölmerich, J., Brynskov, J., D’Haens, G., Hanauer, S. B., Irvine, J. E., Jewell, D. P., Rachmilewitz, D., Sachar, D. B., Sandborn, W. J., et al. (2000) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200002000-00002 · Cited by 1,135 · see citing works
The Alexithymia Construct: A Potential Paradigm for Psychosomatic Medicine
Taylor, G. J., Bagby, R. M., & Parker, J. D. A. (1991) · Psychosomatics · doi:10.1016/s0033-3182(91)72086-0 · Cited by 742 · see citing works
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735 · see citing works
Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment
Musselman, D. L., Betan, E. J., Larsen, H., & Phillips, L. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00569-9 · Cited by 670 · see citing works
Depression and immune function
Kiecolt-Glaser, J. K., & Glaser, R. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(02)00309-4 · Cited by 571 · see citing works
Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI)
Best, W. R., Becktel, J. M., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90384-6 · Cited by 564 · see citing works
Gender differences in the reporting of physical and somatoform symptoms
Kroenke, K., & Spitzer, R. L. (1998) · Psychosomatic Medicine · doi:10.1097/00006842-199803000-00006 · Cited by 559 · see citing works
Mittermaier, C., Dejaco, C., Waldhoer, T., Oefferlbauer-Ernst, A., Miehsler, W., Beier, M., Tillinger, W., Gangl, A., & Moser, G. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000106907.24881.f2 · Cited by 532 · see citing works
Ismail, K., Winkley, K., & Rabe-Hesketh, S. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16202-8 · Cited by 531 · see citing works
Impact of major depression on chronic medical illness
Katon, W., & Ciechanowski, P. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(02)00313-6 · Cited by 485 · see citing works
Stress and Exacerbation in Ulcerative Colitis: A Prospective Study of Patients Enrolled in Remission
Levenstein, S., Prantera, C., Varvo, V., Scribano, M. L., Andreoli, A., Luzi, C., Arcà, M., Berto, E., Milite, G., & Marcheggiano, A. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02012.x · Cited by 451 · see citing works
Tuglu, C., Kara, S. H., Caliyurt, O., Vardar, E., & Abay, E. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1566-z · Cited by 391 · see citing works
Guthrie, E., Jackson, J., Shaffer, J., Thompson, D., Tomenson, B., & Creed, F. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05842.x · Cited by 306 · see citing works
Predictors of response to infliximab in patients with Crohn's disease
Parsi, M. A., Achkar, J., Richardson, S., Katz, J., Hammel, J., Lashner, B. A., & Brzezinski, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.35390 · Cited by 251 · see citing works
Addolorato, G., Capristo, E., Stefanini, G. F., & Gasbarrini, A. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011218 · Cited by 243 · see citing works
Vermeire, S. A. R. A., Louis, E. J., Carbonez, A., et al. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05991.x · Cited by 227 · see citing works
Self-citationPsychosocial determinants of relapse in ulcerative colitis: A longitudinal study
Bitton, A., Sewitch, M. J., Peppercorn, M. A., de B Edwardes, M. D., Shah, S., Ransil, B., & Locke, S. E. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07717.x · Cited by 226 · see citing works
Crohn's disease: monitoring disease activity
Sostegni, R., Daperno, M., Scaglione, N., Lavagna, A., Rocca, R., & Pera, A. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.17.s2.17.x · Cited by 220 · see citing works
Arnott, I. D., McNeill, G., & Satsangi, J. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01574.x · Cited by 196 · see citing works
Psychiatric illness in patients with inflammatory bowel disease.
Andrews, H., Barczak, P., & Allan, R. N. (1987) · Gut · doi:10.1136/gut.28.12.1600 · Cited by 180 · see citing works
Duffy, L. C., Zielezny, M. A., Marshall, J. R., Byers, T. E., Weiser, M. M., Phillips, J. F., Calkins, B. M., Ogra, P. L., & Graham, S. (1991) · Behavioral Medicine · doi:10.1080/08964289.1991.9937553 · Cited by 176 · see citing works
Do Life Events or Depression Exacerbate Inflammatory Bowel Disease?: A Prospective Study
North, C. S., Alpers, D. H., Helzer, J. E., Spitznagel, E. L., & Clouse, R. E. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-5-381 · Cited by 152 · see citing works
Walker, E. A., Gelfand, M. D., Gelfand, A. N., Creed, F., & Katon, W. J. (1996) · General Hospital Psychiatry · doi:10.1016/0163-8343(96)00036-9 · Cited by 144 · see citing works
Addolorato, G., Lorenzi, G. D., Abenavoli, L., Leggio, L., Capristo, E., & Gasbarrini, A. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02193.x · Cited by 116 · see citing works
Long-term monitoring of psychosocial stress and symptomatology in inflammatory bowel disease
Greene, B. R., Blanchard, E. B., & Wan, C. K. (1994) · Behaviour Research and Therapy · doi:10.1016/0005-7967(94)90114-7 · Cited by 100 · see citing works
Verissimo, R., Mota-Cardoso, R., & Taylor, G. (1998) · Psychotherapy and Psychosomatics · doi:10.1159/000012263 · Cited by 90 · see citing works
Psychosocial Aspects of Crohn's Disease
Ringel, Y., & Drossman, D. A. (2001) · Surgical Clinics of North America · doi:10.1016/s0039-6109(05)70283-8 · Cited by 61 · see citing works
A Review of Studies of Psychiatric Factors in Crohn's Disease: Etiologic Implications
North, C. S., & Alpers, D. (1994) · Annals of Clinical Psychiatry · doi:10.3109/10401239409148990 · Cited by 54 · see citing works
Lag Time between Stress Events and Risk of Recurrent Episodes of Inflammatory Bowel Disease
Duffy, L. C., Zielezny, M. A., Marshall, J. R., Weiser, M. M., Phillips, J. F., Byers, T., Calkins, B. M., Graham, S., & Ogra, P. L. O. (1991) · Epidemiology · doi:10.1097/00001648-199103000-00009 · Cited by 43 · see citing works
Flagged first, then by citations
Research works printed but not linked: 10
- Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003; 54: 216-26.
- Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry 2003; 54: 295-306.
- Garrett JW, Drossman DA. Health status in inflammatory bowel disease. Biological and behavioral considerations. Gastroenterology 1990; 99: 90-6.
- von Wietersheim J, Kohler T, Feiereis H. Relapse-precipitating life events and feelings in patients with inflammatory bowel disease. Psychother Psychosom 1992; 58: 103-12.
- Levenstein S, Prantera C, Varvo V, et al. Psychological stress and disease activity in ulcerative colitis: a multidimensional cross-sectional study [see comments]. Am J Gastroenterol 1994; 89: 1219-25.
- Lashner BA. Clinical features, laboratory findings, and course of Crohn's disease. In: Kirsner, JB, ed. Inflammatory Bowel Disease, 5th edn. Chicago, Illinois: W.B. Saunders Company, 2000: 305-314.
- Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
- Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J 2001; 31: 146-50.
- Persoons P, Luyckx K, Fischler B. Psychiatric diagnoses in gastroenterolgy: validation of a self-report instrument (PRIME-MD PHQ), epidemiology and recognition. Gastroenterology 2001; 120: 615.
- Porcelli P, Zaka S, Claudio L, Centonze S, Taylor G. Alexithymia in inflammatory bowel disease. Psychother Psychosom 1995; 64: 49-53.
Cited by
Sorted by citations
Kroenke, K., Spitzer, R. L., Williams, J. B. W., & Löwe, B. (2010) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2010.03.006 · Cited by 4,057 · see citing works
Slavich, G. M., & Irwin, M. R. (2014) · Psychological Bulletin · doi:10.1037/a0035302 · Cited by 2,206 · see citing works
“In addition, whereas only 43% of patients in the placebo group experienced clinically significant improvements in fatigue at Week 12, 58% of those in the etanercept group experienced such improvements (Tyring et al., 2006; see also Persoons et al., 2005).”
BackgroundRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · see citing works
Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1611 · Cited by 941 · see citing works
Inflammation: Depression Fans the Flames and Feasts on the Heat
Kiecolt-Glaser, J. K., Derry, H. M., & Fagundes, C. P. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15020152 · Cited by 844 · see citing works
“disease patients (179) Reduces the ability to fight infection;”
BackgroundBrain–Gut Interactions in Inflammatory Bowel Disease
Bonaz, B. L., & Bernstein, C. N. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.10.003 · Cited by 667 · see citing works
“In a prospective study of CD patients, major depression was a risk factor for failure to achieve remission with infliximab treatment and an earlier need for reinitiation of treatment (105).”
BackgroundInflamed moods: A review of the interactions between inflammation and mood disorders
Rosenblat, J. D., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.013 · Cited by 609 · see citing works
Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management
Graff, L. A., Walker, J. R., & Bernstein, C. N. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20873 · Cited by 586 · see citing works
Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment
Bisgaard, T. H., Allin, K. H., Keefer, L., Ananthakrishnan, A. N., & Jess, T. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00634-6 · Cited by 572 · see citing works
Is depression an inflammatory disorder?
Raison, C. L., & Miller, A. H. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0232-0 · Cited by 524 · see citing works
ACG clinical guideline: Preventive care in inflammatory bowel disease
Farraye, F. A., Melmed, G. Y., Lichtenstein, G. R., & Kane, S. V. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.537 · Cited by 473 · see citing works
Walker, J. R., Ediger, J. P., Graff, L. A., Greenfeld, J. M., Clara, I., Lix, L., Rawsthorne, P., Miller, N., Rogala, L., McPhail, C. M., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01980.x · Cited by 437 · see citing works
“In a prospective study of CD patients, major depression was a risk factor for failure to achieve remission with infliximab treatment and an earlier need for reinitiation of treatment (43).”
BackgroundBi-directionality of brain–gut interactions in patients with inflammatory bowel disease
Gracie, D. J., Guthrie, E. A., Hamlin, P. J., & Ford, A. C. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.027 · Cited by 408 · see citing works
Depression: an inflammatory illness?: Figure 1
Krishnadas, R., & Cavanagh, J. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301779 · Cited by 392 · see citing works
The mucosal immune system: master regulator of bidirectional gut-brain communications
Powell, N., Walker, M. M., & Talley, N. J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.191 · Cited by 379 · see citing works
Mikocka-Walus, A., Pittet, V., Rossel, J.-B., von Känel, R., Anderegg, C., Bauerfeind, P., Beglinger, C., Begré, S., Belli, D., Bengoa, J. M., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.12.045 · Cited by 348 · see citing works
Cognitive Impairment in Major Depressive Disorder
Pan, Z., Park, C., Brietzke, E., Zuckerman, H., Rong, C., Mansur, R. B., Fus, D., Subramaniapillai, M., Lee, Y., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852918001207 · Cited by 320 · see citing works
“Evidence also demonstrates efficacy of TNF antagonists in subgroups with treatment-resistant depression.(76,77) Whether adjunctive infliximab is an efficacious approach to treating cognitive symptoms in depressive mood disorders has yet to be determined but is currently being investigated by our group in Toronto (NCT0…”
BackgroundGracie, D. J., Hamlin, P. J., & Ford, A. C. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30089-5 · Cited by 358 · see citing works
Increased burden of psychiatric disorders in inflammatory bowel disease
Bernstein, C. N., Hitchon, C. A., Walld, R., Bolton, J. M., Sareen, J., Walker, J. R., Graff, L. A., Patten, S. B., Singer, A., Lix, L. M., et al. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy235 · Cited by 274 · see citing works
Fairbrass, K. M., Lovatt, J., Barberio, B., Yuan, Y., Gracie, D. J., & Ford, A. C. (2022) · Gut · doi:10.1136/gutjnl-2021-325985 · Cited by 225 · see citing works
Evidence for a Dysregulated Immune System in the Etiology of Psychiatric Disorders
Gibney, S. M., & Drexhage, H. A. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9462-8 · Cited by 237 · see citing works
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 234 · see citing works
Chen, L.-M., Bao, C., Wu, Y. H., Liang, S.-H., Wang, D., Wu, L.-Y., Huang, Y., Liu, H.-R., & Wu, H.-G. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02175-2 · Cited by 239 · see citing works
Goodhand, J. R., Wahed, M., Mawdsley, J. E., Farmer, A. D., Aziz, Q., & Rampton, D. S. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22916 · Cited by 234 · see citing works
“Socioeconomic status ACORN type (Median [range]) 21 [1-56] 33 [1-56] — 0.”
Ma, K., Zhang, H., & Baloch, Z. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050733 · Cited by 205 · see citing works
“also reported the beneficial effects of infliximab on depression and psychological well-being in active CD [134].”
BackgroundFond, G. B., Hamdani, N., Kapczinski, F. P., Boukouaci, W., Drancourt, N., Dargél, A., Oliveira, J., Guen, E. L., Marlinge, E., Tamouza, R., et al. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12211 · Cited by 172 · see citing works
“Peripheral administration of infliximab has been shown to improve depressed mood in patients with Crohn disease (145).”
BackgroundMikocka-Walus, A. A., Turnbull, D. A., Moulding, N. T., Wilson, I. G., Andrews, J. M., & Holtmann, G. J. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20062 · Cited by 178 · see citing works
Novel therapeutic targets in depression: Minocycline as a candidate treatment
Soczynska, J. K., Mansur, R. B., Brietzke, E. M., Swardfager, W., Kennedy, S. H., Woldeyohannes, H. O., Powell, A. M., Manierka, M. S., & McIntyre, R. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.026 · Cited by 190 · see citing works
Influences and impact of anxiety and depression in the setting of inflammatory bowel disease
Navabi, S., Gorrepati, V. S., Yadav, S., Chintanaboina, J., Maher, S., Demuth, P., Stern, B., Stuart, A., Tinsley, A., Clarke, K., et al. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy143 · Cited by 172 · see citing works
Abautret-Daly, Á., Dempsey, E., Parra‐Blanco, A., Medina, C., & Harkin, A. (2017) · Acta Neuropsychiatrica · doi:10.1017/neu.2017.3 · Cited by 185 · see citing works
“Persoons et al. (52) also reported decreased remission rates in patients with a major depressive disorder.”
Bortolato, B., F. Carvalho, A., K. Soczynska, J., I. Perini, G., & S. McIntyre, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630171433 · Cited by 142 · see citing works
“Results from another prospective study in patients with active CD (n=100) reported a beneficial effect of IFX treatment on depression scores in the Patient Health Questionnaire 9-items (PHQ-9) [121].”
BackgroundEtiology and Treatment of Pain and Psychosocial Issues in Patients With Inflammatory Bowel Diseases
Regueiro, M., Greer, J. B., & Szigethy, E. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.036 · Cited by 142 · see citing works
Adolescents with IBD: The importance of structured transition care
Goodhand, J., Hedin, C. R. H., Croft, N. M., & Lindsay, J. O. (2011) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2011.03.015 · Cited by 129 · see citing works
The Depressed Frail Phenotype: The Clinical Manifestation of Increased Biological Aging
Brown, P. J., Rutherford, B. R., Yaffe, K. S., Tandler, J. M., Ray, J. L., Pott, E., Chung, S., & Roose, S. P. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.06.005 · Cited by 141 · see citing works
Goodhand, J., Greig, F. I. S., Koodun, Y., Mcdermott, A., Wahed, M., Langmead, L., & Rampton, D. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21846 · Cited by 131 · see citing works
“Disease duration Median age at diagnosis (yrs) [range] 26 [13–72] 29 [12-62] 0.”
BackgroundCarvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123 · see citing works
Mapping inflammation onto mood: inflammatory mediators of anhedonia
Swardfager, W., Rosenblat, J. D., Benlamri, M., & McIntyre, R. S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.017 · Cited by 125 · see citing works
Therapeutic Strategies for Treatment of Inflammation-related Depression
Adžić, M., Brkic, Z., Mitić, M., Francija, E., Jovicic, M. J., Radulović, J., & Marić, N. P. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170828163048 · Cited by 156 · see citing works
“Infliximab also had beneficial effects on depression in patients suffering from ankylosing spondylitis [142] and CD [143].”
BackgroundPsychiatric co‐morbidity is associated with increased risk of surgery in Crohn's disease
Ananthakrishnan, A. N., Gainer, V. S., Perez, R. G., Cai, T., Cheng, S. ‐., Savova, G., Chen, P., Szolovits, P., Xia, Z., De Jager, P. L., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12195 · Cited by 122 · see citing works
Sofia, M. A., Ciorba, M. A., Meckel, K. R., Lim, C. K., Guillemin, G. J., Weber, C. R., Bissonnette, M., & Pekow, J. R. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy103 · Cited by 142 · see citing works
Ertenli, İ., Ozer, S., Kiraz, S., Apras, S., Akdoğan, A., Karadağ, Ö., Çalgünerı, M., & Kalyoncu, U. (2010) · Rheumatology International · doi:10.1007/s00296-010-1616-x · Cited by 129 · see citing works
“The findings in active CD [13–15] suggest that infliximab rapidly and significantly reduced depression scores, prior to any improvement in the intestinal pathology.”
BackgroundResultS3-Leitlinie „Diagnostik und Therapie des Morbus Crohn”
Hoffmann, J., Preiß, J., Autschbach, F., Buhr, H. J., Häuser, W., Herrlinger, K. R., Höhne, W., Koletzko, S., Krieglstein, C. F., Kruis, W., et al. (2008) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027796 · Cited by 134 · see citing works
Systematic review: psychosocial factors associated with pain in inflammatory bowel disease
Sweeney, L., Moss‐Morris, R., Czuber‐Dochan, W., Meade, L., Chumbley, G., & Norton, C. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14493 · Cited by 112 · see citing works
Cámara, R. J. A., Ziegler, R., Begré, S., Schoepfer, A. M., & von Känel, R. (2009) · Digestion · doi:10.1159/000226087 · Cited by 106 · see citing works
Psychological stress and depression: risk factors for IBD
Bernstein, C. N. (2016) · Digestive Diseases · doi:10.1159/000442929 · Cited by 107 · see citing works
The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases
Peppas, S., Pansieri, C., Piovani, D., Danese, S., Peyrin‐Biroulet, L., Tsantes, A. G., Brunetta, E., Tsantes, A. Ε., & Bonovas, S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030377 · Cited by 114 · see citing works
Minderhoud, I. M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i14.2089 · Cited by 100 · see citing works
“We also demonstrated a beneficial effect of infliximab on feelings of mental depression or psychological wellbeing, as did Persoons et al recently [ 32 ]”
BackgroundAnti-TNF-α Compounds as a Treatment for Depression
Uzzan, S., & Azab, A. N. (2021) · Molecules · doi:10.3390/molecules26082368 · Cited by 109 · see citing works
“Crohn’s disease All patients were treated with infliximab + standard therapy (4 weeks) Significant decrease in the proportion of depressed patients [134]”
BackgroundPermanent Work Disability in Crohn's Disease
Ananthakrishnan, A. N., Weber, L. R., Knox, J. F., Skaros, S., Emmons, J. E., Lundeen, S. J., Issa, M., Otterson, M. F., & Binion, D. G. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01561.x · Cited by 95 · see citing works
“Psychiatric illness has been recognized as a significant factor in the clinical course of CD and is associated with lower HRQOL and decreased response to therapy (22, 23).”
BackgroundDifficult-to-treat inflammatory bowel disease: results from an international consensus meeting
Parigi, T. L., D’Amico, F., Abreu, M. T., Dignass, A. U., Dotan, I., Magro, F., Griffiths, A. M., Jairath, V., Iacucci, M., Mantzaris, G. J., et al. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00154-1 · Cited by 128 · see citing works
Soczynska, J. K., Kennedy, S. H., Goldstein, B. I., Lachowski, A. M., Woldeyohannes, H. O., & McIntyre, R. S. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.03.004 · Cited by 93 · see citing works
Antidepressants in inflammatory bowel disease
Mikocka-Walus, A., Ford, A. C., & Drossman, D. A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0259-y · Cited by 93 · see citing works
Psychosomatic Medicine: The Scientific Foundation of the Biopsychosocial Model
Novack, D. H., Cameron, O. G., Epel, E. S., Ader, R., Waldstein, S. R., Levenstein, S., Antoni, M. H., & Wainer, A. (2007) · Academic Psychiatry · doi:10.1176/appi.ap.31.5.388 · Cited by 92 · see citing works
“Clinical exacerbation has been found to be facilitated by life stress in ulcerative colitis (117) and by depressive symptoms in Crohn’s disease (120, 121), though life stress is unlikely to cause disease onset (122).”
BackgroundPsoriasis, Depression, and Inflammatory Overlap: A Review
Patel, N., Nadkarni, A., Cardwell, L. A., Vera, N., Frey, C. D., Patel, N. N., & Feldman, S. R. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0279-8 · Cited by 92 · see citing works
Réus, G. Z., Manosso, L. M., Quevedo, J., & Carvalho, A. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105425 · Cited by 89 · see citing works
Visceral Inflammation and Immune Activation Stress the Brain
Holzer, P., Farzi, A., Hassan, A. M., Zenz, G., Jačan, A., & Reichmann, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01613 · Cited by 84 · see citing works
“Moreover, the psychiatric comorbidities can affect disease prognosis and response to treatment, as Crohns’ disease patients with major depression respond poorly to infliximab (259).”
BackgroundNeilson, K., Ftanou, M., Monshat, K., Salzberg, M., Bell, S., Kamm, M. A., Connell, W., Knowles, S. R., Sevar, K., Mancuso, S. G., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000629 · Cited by 80 · see citing works
“A growing body of research is providing evidence that ongoing psychological distress may also lead to increased IBD activity and increased risk of flares.(15,18,19) Furthermore, psychosocial stressors have been implicated in triggering flare-ups of symptoms in both animal and human studies.”
BackgroundImmune-based strategies for mood disorders: facts and challenges
Colpo, G. D., Leboyer, M., Dantzer, R., Trivedi, M. H., & Teixeira, A. L. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1407242 · Cited by 90 · see citing works
Weinberger, J. F., Raison, C. L., Rye, D. B., Montague, A. R., Woolwine, B. J., Felger, J. C., Haroon, E., & Miller, A. H. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.12.016 · Cited by 86 · see citing works
“Interestingly, TNF is reliably elevated in depressed patients (Dowlati et al. 2010), and TNF blockade has been shown to have antidepressant activity in inflammatory and autoimmune diseases including psoriasis and Crohn’s disease (Persoons et al. 2005; Tyring et al. 2006).”
Serotonin Synthesis and Uptake in Symptomatic Patients With Crohn’s Disease in Remission
Minderhoud, I. M., Oldenburg, B., Schipper, M. E. I., Linde, J. J. M. T., & Samsom, M. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.02.013 · Cited by 69 · see citing works
Dubinsky, M. C., Dotan, I., Rubin, D. T., Bernauer, M. J., Patel, D. A., Cheung, R. Y., Modesto, I., Latymer, M., & Keefer, L. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1911644 · Cited by 92 · see citing works
Hlavatý, T., Ferrante, M., Henckaerts, L., Pierik, M., Rutgeerts, P., & Vermeire, S. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20024 · Cited by 77 · see citing works
Self-citationPain Management in Patients with Inflammatory Bowel Disease
Srinath, A. I., Young, E. E., & Szigethy, E. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000170 · Cited by 82 · see citing works
“Psychological dysfunction has been shown to amplify symptom severity, particular abdominal pain perception,(52,65,66) in chronic medical illness.(51) Specifically, there have been adult and pediatric studies demonstrating the presence of functional abdominal pain (i.”
BackgroundPsoriasis y depresión: el papel de la inflamación
González‐Parra, S., & Daudén, E. (2018) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2018.05.009 · Cited by 67 · see citing works
“Aunque disponemos de numerosos datos sobre esta”
The role of inflammatory cytokines on the aetiopathogenesis of depression
Makhija, K., & Karunakaran, S. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413488220 · Cited by 76 · see citing works
“The authors study suggested this may be due to an underlying immune dysregulation and enhanced cytokine production in patients with MDD (Persoons et al., 2005).”
BackgroundFlett, G. L., Baricza, C., Gupta, A., Hewitt, P. L., & Endler, N. S. (2011) · Journal of Health Psychology · doi:10.1177/1359105310383601 · Cited by 62 · see citing works
“A related possibility is that the current findings reflect, in part, the role of chronic depression, since perfectionism is often linked with depression and depression tends to be associated with non-remission of Crohn’s disease after treatment (Persoons et al., 2005).”
BackgroundVitamin D Therapy in Inflammatory Bowel Diseases: Who, in What Form, and How Much?
Hlavatý, T., Krajčovičová, A., & Payer, J. (2014) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jju004 · Cited by 72 · see citing works
Psoriasis and Depression: The Role of Inflammation
González-Parra, S., & Daudén, E. (2019) · Actas Dermo-Sifiliográficas (English Edition) · doi:10.1016/j.adengl.2018.05.035 · Cited by 70 · see citing works
“Studies with infliximab have reported similar results, such as enhanced quality of life and improvements in other aspects of psoriasis and in the symptoms of depression in patients with Crohn disease.(50,73,74) In the case of adalimumab, authors report improvements in physical functioning and the social and psychologi…”
ResultBiesmans, S., Bouwknecht, J. A., Donck, L. V., Langlois, X., Acton, P. D., Haes, P. D., Davoodi, N., Meert, T. F., Hellings, N., & Nuydens, R. (2015) · BioMed Research International · doi:10.1155/2015/716920 · Cited by 75 · see citing works
“Furthermore, peripheral administration of anti-TNF-α antibodies improves depressed mood in patients suffering from psoriasis [17], Crohn’s disease [18], and rheumatoid arthritis [19].”
BackgroundManagement of inflammatory bowel disease with vitamin D: Beyond bone health
Narula, N., & Marshall, J. K. (2011) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2011.10.015 · Cited by 62 · see citing works
Alexakis, C., Kumar, S., Saxena, S., & Pollok, R. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14171 · Cited by 69 · see citing works
“Only one paper examined depressive state as the unique exposure.(32) All the studies would have been prone to referral centre bias, with the probable exception of Camara et al.”
BackgroundMethodInfluentialMargulies, S. L., Kurian, D., Elliott, M. S., & Han, Z. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12283 · Cited by 70 · see citing works
Does psychological counseling alter the natural history of inflammatory bowel disease?
Wahed, M., Corser, M., Goodhand, J., & Rampton, D. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21098 · Cited by 69 · see citing works
Horst, S., Chao, A., Rosen, M., Nohl, A., Duley, C., Wagnon, J. H., Beaulieu, D. B., Taylor, W., Gaines, L., & Schwartz, D. A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3375-0 · Cited by 75 · see citing works
“[16] found that following a single infusion of infliximab, a significantly lower proportion of patients with CD (n = 100) met criteria for major depressive disorder (24–16 %, p \ 0.”
BackgroundMoraes, M. M. T., Galvão, M. C., Cabral, D., Coelho, C. D. P., Queiroz‐Hazarbassanov, N., Martins, M. D. F. M., Bondan, E. F., Bernardi, M. M., & Kirsten, T. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169446 · Cited by 55 · see citing works
Bhandari, S., Larson, M. E., Kumar, N., & Stein, D. (2017) · Gut and Liver · doi:10.5009/gnl16347 · Cited by 66 · see citing works
“Depression in the setting of IBD is also associated with decreased adherence to treatment regimens(8) as well as decreasing short and long term efficacy of infliximab treatment.(9) Given that depression worsens outcomes for IBD patients, it is helpful to understand the prevalence of depression in IBD patients.”
BackgroundThe Inflammatory Bowel Disease Specialty Medical Home
Regueiro, M. D., McAnallen, S., Greer, J. B., Perkins, S., Ramalingam, S., & Szigethy, E. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000819 · Cited by 72 · see citing works
Gray, M. A., Chao, C.-Y., Staudacher, H. M., Kolosky, N. A., Talley, N. J., & Holtmann, G. (2018) · PLOS ONE · doi:10.1371/journal.pone.0193542 · Cited by 63 · see citing works
Dempsey, E., Abautret-Daly, Á., Docherty, N. G., Medina, C., & Harkin, A. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.05.007 · Cited by 67 · see citing works
Kalla, R., Ventham, N. T., Satsangi, J., & Arnott, I. D. (2014) · BMJ · doi:10.1136/bmj.g6670 · Cited by 89 · see citing works
Repeated predictable stress causes resilience against colitis-induced behavioral changes in mice
Hassan, A. M., Jain, P., Reichmann, F., Mayerhofer, R., Farzi, A., Schuligoi, R., & Holzer, P. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00386 · Cited by 59 · see citing works
The Influence of Stress on the Development and Severity of Immune-Mediated Diseases
Rampton, D. S. (2011) · Journal of Rheumatology Supplement · doi:10.3899/jrheum.110904 · Cited by 51 · see citing works
Brietzke, E., Stabellini, R., Grassi-Oliveira, R., & Lafer, B. (2011) · CNS Spectrums · doi:10.1017/s1092852912000338 · Cited by 57 · see citing works
Management of stress in inflammatory bowel disease: a therapeutic option?
Goodhand, J., Wahed, M., & Rampton, D. S. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.55 · Cited by 56 · see citing works
Wei, W., Sayyid, Z. N., Ma, X., Wang, T., & Dong, Y. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00178 · Cited by 61 · see citing works
Depression and Inflammation: Disentangling a Clear Yet Complex and Multifaceted Link
Amodeo, G., Trusso, M. A., & Fagiolini, A. M. (2017) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000236 · Cited by 52 · see citing works
“Also, greater remission of depressive symptoms with the TNF-α antagonist infliximab were seen in Crohn’s disease patients [39], while TNF-α antagonists have shown efficacy in patients with depression within the context of autoimmune disorders or other conditions with increased inflammation [40,41].”
BackgroundMind and body: how the health of the body impacts on neuropsychiatry
Renoir, T., Hasebe, K., & Gray, L. J. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00158 · Cited by 62 · see citing works
“Drugs with a similar TNF-α antagonist activity have also shown antidepressant activity in trials in patients with other inflammatory conditions, including Crohn’s disease and ankylosing spondylitis (Persoons et al., 2005; Ertenli et al., 2012).”
BackgroundInflammatory Biomarkers in Depression: An Opportunity for Novel Therapeutic Interventions
Li, M., Soczynska, J. K., & Kennedy, S. H. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0210-6 · Cited by 53 · see citing works
“There are also reports that individuals with autoimmune or inflammatory disorders who are treated with a TNF-α inhibitor experience a reduction in depressive symptoms [43–46].”
BackgroundInfluence of environmental factors on the onset and course of inflammatory bowel disease
Dutta, A. K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.1088 · Cited by 51 · see citing works
Anxiety but not depression predicts poor outcomes in inflammatory bowel disease
Narula, N., Pinto-Sanchez, M. I., Calo, N. C., Ford, A. C., Bercik, P., Reinisch, W., & Moayyedi, P. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy385 · Cited by 52 · see citing works
“A number of other studies have previously examined the association between psychological comorbidity and IBD outcomes, but many are limited by being retrospective or cross-sectional [28-30], or”
BackgroundCollins, S. M. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa004 · Cited by 61 · see citing works
Psychological factors and stress in inflammatory bowel disease
Triantafillidis, J. K., Merikas, E., & Gikas, A. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.13.4 · Cited by 50 · see citing works
Nitric oxide: Antidepressant mechanisms and inflammation
Ghasemi, M. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.04.004 · Cited by 49 · see citing works
Iglesias, M., de Acosta, M. B., Vázquez, I., Figueiras, A., Nieto, L., Lorenzo, A., & Domínguez‐Muñoz, J. E. (2009) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082009000400003 · Cited by 44 · see citing works
5-HT7 receptor signaling: improved therapeutic strategy in gut disorders
Kim, J., & Khan, W. I. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00396 · Cited by 49 · see citing works
Predictors of Hospital Readmissions for Ulcerative Colitis in the United States
Poojary, P., Saha, A., Chauhan, K., Simoes, P. K., Sands, B. E., Cho, J. H., Ullman, T. A., Nadkarni, G. N., & Ungaro, R. C. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001041 · Cited by 44 · see citing works
Prescription of physical exercise in Crohn's disease
Pérez, C. A. (2009) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2009.08.006 · Cited by 41 · see citing works
ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease
Farraye, F. A., Melmed, G., Lichtenstein, G. R., Barnes, E. L., Limketkai, B. N., Caldera, F., & Kane, S. V. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003541 · Cited by 44 · see citing works
Calvet, X., Gallardo, O., Coronas, R., Casellas, F., Montserrat, A., Torrejón, A., Vergara, M., Campo, R., & Brullet, E. (2006) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200608000-00004 · Cited by 45 · see citing works
for the CIHR Team “Defining the burden and managing the effects of psychiatric comorbidity in chronic immunoinflammatory disease”, Fiest, K. M., Bernstein, C. N., Walker, J. R., Graff, L. A., Hitchon, C. A., PESCHKEN, C. A., Zarychanski, R., Abou-Setta, A. M., Patten, S. B., et al. (2016) · BMC Research Notes · doi:10.1186/s13104-016-2204-2 · Cited by 46 · see citing works
“In active Crohn’s disease, depression is associated with a failure to achieve remission on infliximab and earlier retreatment [10].”
Background
- Authors
- PERSOONS, P., VERMEIRE, S., DEMYTTENAERE, K., FISCHLER, B., VANDENBERGHE, J., VAN OUDENHOVE, L., PIERIK, M., HLAVATY, T., VAN ASSCHE, G., NOMAN, M., & RUTGEERTS, P.
- Affiliations
- KU Leuven (BE)
- Corresponding author
- RUTGEERTS, P.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-07
- Volume
- 22
- Issue
- 2
- Pages
- 101-110
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2025629977
- Cited by
- 253
- References
- 0
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 12 · 2023: 12 · 2022: 17 · 2021: 13 · 2020: 9 · 2019: 16 · 2018: 19 · 2017: 18 · 2016: 19 · 2015: 15 · 2014: 18 · 2013: 13 · 2012: 9
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- green
- lirias.kuleuven.be
- Licence
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- Funders
- Vlaamse regering
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- major depressive disorder, Crohn's disease, infliximab, treatment response, remission, retreatment, disease flares, psychiatric comorbidity, luminal Crohn's disease, biologic therapy
- MeSH terms
- Infliximab, Adult, Affective Symptoms, Antibodies, Monoclonal, Anxiety, Crohn Disease, Depressive Disorder, Major, Major Depressive Disorder, Female, Gastrointestinal Agents, Humans, Male, Prospective Studies, Regression Analysis, Risk Factors, Sleep Wake Disorders, Social Support, Multivariate Analysis, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
